Filtered By:
Specialty: Hematology
Condition: Obesity
This page shows you your search results in order of date.
Order by Relevance | Date
Total 37 results found since Jan 2013.
Clinical effectiveness and safety of edoxaban in obese patients — Results of the prospective Dresden NOAC Registry (NCT01588119)
Edoxaban is a direct factor Xa inhibitors approved for stroke prevention in atrial fibrillation (SPAF) and for venous thromboembolism (VTE) treatment. Edoxaban is given in a fixed dosing regimen (with recommended dose reductions for patients with renal impairment or body weight
Source: Thrombosis Research - June 2, 2023 Category: Hematology Authors: Luise Tittl, Christina K öhler, Sandra Marten, Christiane Naue, Kristina Fache, Laura Stanneck, Thomas Schreier, Jan Beyer-Westendorf Tags: Letter to the Editors-in-Chief Source Type: research
Treatment-related Correlates of Growth in Children With Sickle Cell Disease in the DISPLACE Cohort
This study investigated growth and hemolysis in children with SCD in the DISPLACE (Dissemination and Implementation of Stroke Prevention Looking at the Care Environment) cohort. The database includes 5287 children, of which, 3305 had at least 2 growth measurements over a 5-year period. Body mass index was converted to z-scores (zBMI), and 19.8%, 66.1%, 14.2% of children were classified as underweight, normal, and overweight/obese, respectively. Multivariable analysis of growth was conducted and included variables: age, sex, blood pressure, hemoglobin, reticulocyte count, treatment with chronic red cell transfusion therapy ...
Source: Journal of Pediatric Hematology Oncology - June 30, 2022 Category: Hematology Tags: Original Articles Source Type: research
Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study
The benefit of apixaban to reduce stroke risk in morbidly obese patients with nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of Thrombosis and Hemostasis recommends avoid...
Source: Thrombosis Journal - May 2, 2022 Category: Hematology Authors: Khalid Al Sulaiman, Hisham A. Badreldin, Ghazwa B. Korayem, Abeer A. Alenazi, Faisal Alsuwayyid, Abdulrahman Alrashidi, Mohammed Alhijris, Faisal Almutairi, Fahad Alharthi, Ramesh Vishwakarma, Omar Al Shaya, Abdulrahman Al Amri, Saqiba Tayyab, Abdulkareem Tags: Research Source Type: research
Incidence of thrombotic complications related to weight-based dosing of activated prothrombin complex concentrate (aPCC) for reversal of apixaban and rivaroxaban in obese patients
AbstractFactor eight inhibitor bypassing activity (aPCC) is recommended as a non-specific reversal agent for direct oral anticoagulants (DOACs) according to the 2017 American College of Cardiology (ACC) guidelines for reversal of anticoagulation. Factor eight inhibitor bypassing activity carries a black box warning for thrombotic events such as stroke, pulmonary embolism, deep vein thrombosis, and myocardial infarction, particularly at high doses. This was a retrospective, single-center, cohort investigation that included patients who received a weight-based dose of aPCC for reversal of apixaban and rivaroxaban between Jan...
Source: Journal of Thrombosis and Thrombolysis - November 17, 2021 Category: Hematology Source Type: research
Extended-Duration Low-intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism: Design of the HI-PRO Trial
Thromb Haemost. 2021 Sep 16. doi: 10.1055/a-1646-2244. Online ahead of print.ABSTRACTPatients with acute venous thromboembolism (VTE) in the setting of transient provoking factors are typically treated with short-term anticoagulation. However, the risk of recurrence may be increased in the presence of enduring risk factors. In such patients, the optimal duration of treatment remains uncertain. HI-PRO is a single-center, double-blind randomized trial. Patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) following a major provoking factor, including major surgery or major trauma, who completed at least 3 month...
Source: Thrombosis and Haemostasis - September 16, 2021 Category: Hematology Authors: Behnood Bikdeli Heather Hogan Ruth Morrison John Fanikos Umberto Campia Briana Barns Mariana Pfeferman Julia Snyder Candrika Khairani Samuel Z Goldhaber Gregory Piazza Source Type: research
Oral anticoagulant use in patients with morbid obesity: A systematic review and meta-analysis
CONCLUSIONS: Patients with morbid obesity on DOACs had similar risks of stroke/systemic embolism, lower rates of recurrent VTE and major bleeding events compared to those on VKAs. However, the certainty of evidence was low given that studies were mostly observational with high risk of confounding.PMID:34399433 | DOI:10.1055/a-1588-9155
Source: Thrombosis and Haemostasis - August 16, 2021 Category: Hematology Authors: Tzu-Fei Wang Marc Carrier Karine Fournier Deborah M Siegal Gr égoire Le Gal Aur élien Delluc Source Type: research
Maximum intravenous Alteplase dose for obese stroke patients is not associated with greater likelihood of worse outcomes
We examined differences between patients treated with WBD vs. MD.
Source: Thrombosis Research - June 6, 2021 Category: Hematology Authors: Kaushik Ravipati, Roboan Guillen, Starlie Belnap, Anshul Saxena, Emir Veledar, Amy K. Starosciak, Felipe De Los Rios La Rosa Source Type: research
Clinical Performance of Nonvitamin K Antagonist Oral Anticoagulants in Real-World Obese Patients with Atrial Fibrillation
Semin Thromb Hemost DOI: 10.1055/s-0040-1715792The prevalence of both atrial fibrillation (AF) and obesity has steadily increased. Nonvitamin K antagonist oral anticoagulants (NOACs) have been shown to be more effective and safer than vitamin K antagonists (VKAs) for long-term stroke prevention in patients with nonvalvular AF. There are still limited data in the literature regarding performance of NOACs in obese patients with AF in the “real world.” The aim of our study was to compare the safety and effectiveness of NOACs versus well-controlled VKA therapy in obese AF patients in a “real-world” setting. Here, we ha...
Source: Seminars in Thrombosis and Hemostasis - October 26, 2020 Category: Hematology Authors: Russo, Vincenzo Bottino, Roberta Rago, Anna Papa, Andrea Antonio Liccardo, Biagio D'Onofrio, Antonio Golino, Paolo Nigro, Gerardo Tags: Review Article Source Type: research
New-Onset Atrial Fibrillation in Sepsis: A Narrative Review
Semin Thromb Hemost DOI: 10.1055/s-0040-1714400Atrial fibrillation (AF) is a frequently identified arrhythmia during the course of sepsis. The aim of this narrative review is to assess the characteristics of patients with new-onset AF related to sepsis and the risk of stroke and death, to understand if there is a need for anticoagulation. We searched for studies on AF and sepsis on PubMed, the Cochrane database, and Web of Science, and 17 studies were included. The mean incidence of new-onset AF in patients with sepsis was 20.6% (14.7% in retrospective studies and 31.6% in prospective). Risk factors for new-onset AF includ...
Source: Seminars in Thrombosis and Hemostasis - September 22, 2020 Category: Hematology Authors: Aibar, Jesus Schulman, Sam Tags: Review Article Source Type: research
Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies
AbstractIn October 2019, a viral infectious disease appeared in the city of Wuhan in China. A new betacoronavirus, SARS-CoV-2, has been recognized as the responsible pathogen in this infection. Although coronavirus disease is principally expressed as a pulmonary infection, critical SARS-CoV-2 infection is frequently complicated with coagulopathy, and thromboembolic events are recognizable in several patients. Dehydration, acute inflammatory condition, protracted immobilization during disease, existence of multiple cardiovascular risk factors such as diabetes, obesity or hypertension, previous coronary artery disease, ische...
Source: Annals of Hematology - August 13, 2020 Category: Hematology Source Type: research
Modulators of platelet function in aging.
Authors: Iyer KS, Dayal S
Abstract
Platelets are small, anucleated effector cells that play an important role in linking the hemostatic and inflammatory processes in the body. Platelet function is known to be altered under various inflammatory conditions including aging. A gain in platelet function during aging can increase the risk of thrombotic events, such as stroke and acute myocardial infarction. Anti-platelet therapy is designed to reduce risk of serious cerebrovascular and cardiovascular events, but the adverse consequences of therapy, such as risk for bleeding increases with aging as well. Age-associated co...
Source: Platelets - September 18, 2019 Category: Hematology Tags: Platelets Source Type: research
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data
Publication date: Available online 24 May 2019Source: The Lancet HaematologyAuthor(s): Margarita Kushnir, Yun Choi, Ruth Eisenberg, Devika Rao, Seda Tolu, Jackson Gao, Wenzhu Mowrey, Henny H BillettSummaryBackgroundBecause studies of direct oral anticoagulants in patients with venous thromboembolism and non-valvular atrial fibrillation have had minimal representation of morbidly obese patients (ie, body-mass index [BMI] ≥40 kg/m2), their efficacy and safety in this population are unclear. We investigated whether apixaban and rivaroxaban are as effective and safe as warfarin in morbidly obese patients.MethodsWe did a sing...
Source: The Lancet Haematology - May 26, 2019 Category: Hematology Source Type: research
The pleiotropic effect of rs7903146 on type 2 diabetes and ischemic stroke: a family-based study in a Chinese population
In conclusion, our study provided evidence that a T2D-independent path was identified out of the pleiotropic effect of rs7903146 on IS. However, further studies were needed to validate the biological mechanisms behind the pleiotropic effect and the modification by l ifestyle intervention.
Source: Journal of Thrombosis and Thrombolysis - April 11, 2019 Category: Hematology Source Type: research
